Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Cash Flows From Operating Activities:
Net loss	$ (4,337,312)	$ (2,365,241)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	949,945
Non-cash operating lease expense	36,305	35,325
Depreciation	1,398	6,691
Changes in operating assets and liabilities
Short term receivables		465
Prepaid expenses and other current assets	390,778	267,991
Accounts payable	71,225	(294,892)
Unearned grant revenue	(336,108)	(602,808)
Accrued interest	155,064	166,327
Other accrued expenses	648,909	449,721
Operating lease liability	(36,642)	(35,662)
Net Cash Used In Operating Activities	(2,456,438)	(2,372,083)
Cash Flows From Financing Activities:
Proceeds from issuance of convertible notes payable	550,000	353,000
Proceeds from issuance of convertible notes payable - related parties	975,000	1,950,000
Proceeds from issuance of common stock of majority-owned subsidiary	700,000
Repayment of note payable	(186,223)	(243,554)
Repayment of 2021 convertible note payable - related party		(100,000)
Net Cash Provided By Financing Activities	2,038,777	1,959,446
Effect of exchange rates on cash and restricted cash	414	27
Net Decrease In Cash and Restricted Cash	(417,247)	(412,610)
Cash and Restricted Cash, Beginning of Period	489,726	1,026,799
Cash and Restricted Cash, End of Period	72,479	614,189
Cash	72,479	187,457
Restricted cash		426,732
Supplemental Disclosures of Cash Flow Information:
Interest	4,305	5,439
Income taxes
Non-cash investing and financing activities:
Conversion of 2022 Notes and related accrued interest to Series D-1 Preferred Stock	1,770,603	2,404,057
Conversion of 2024 Notes and related accrued interest to Series D-1 Preferred Stock	718,565
Conversion of accrued directors’ fees to Series D-1 Preferred Stock		2,131,839
ROU asset in exchange for lease liability	150,133
Purchase of insurance policies financed by short-term note payable	(71,904)	(76,283)
Prepaid software financed by note payable	(95,070)
Forfeited shares of Series D Preferred Stock		(11,416)
Issuance of Series D-1 Preferred Stock for forfeited shares of Series D Preferred Stock		$ 1,141

PROVECTUS BIOPHARMACEUTICALS, INC. 10-Q